ATXI
Avenue Therapeutics, Inc.
Industry
Biotechnology
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Loading...
Open
2.26
Mkt cap
3.3M
Volume
8.5K
High
2.29
P/E Ratio
0.06
52-wk high
26.48
Low
2.19
Div yield
N/A
52-wk low
1.70

Portfolio Pulse from Benzinga Newsdesk
April 24, 2024 | 1:09 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.